Drug intelligence / Profile preview

ketamine + morphine

Development stage
Unknown
Modality
Small Molecules
Administration
Intravenous, Subcutaneous, Intramuscular, Epidural, Intrathecal, Oral
01

Overview

Ketamine + morphine is a combination of two analgesic drugs used together primarily for the management of moderate to severe pain, especially in perioperative, emergency, and chronic pain settings. Ketamine is a rapid-acting dissociative anesthetic and N-methyl-D-aspartate (NMDA) receptor antagonist that provides analgesia by inhibiting excitatory neurotransmission involved in pain pathways. Morphine is an opioid agonist that acts mainly on mu-opioid receptors to produce potent analgesia. When combined, ketamine and morphine have been shown to provide synergistic or additive effects on pain relief, potentially reducing opioid requirements and attenuating the development of opioid tolerance. This combination may also be used when single-agent therapy is insufficient or when minimizing opioid dosage is desired due to side effect profiles[2][4][10].

Brand names
MKO Melt Dose PackMKH Dose Pack
Other names
PCA ketamine-morphineketamine-morphine combination
02

Targets

MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on ketamine + morphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketamine + morphine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call